Beta Bionics, Inc. (BBNX)

Beta Bionics, Inc. is a medical device company focused on automated insulin delivery for people with diabetes. Its main product is the iLet Bionic Pancreas, an insulin pump system that uses adaptive algorithms and data from a continuous glucose monitor to determine and deliver insulin doses automatically.

A distinctive feature of the iLet is that it does not require users to count carbohydrates or set traditional pump parameters such as basal rates and correction factors; the system is initialized mainly with body weight and then adapts to the user over time. The device is cleared in the United States for people with type 1 diabetes aged six and older, and the company is pursuing further product development, including a bihormonal system.

Beta Bionics is headquartered in Irvine, California, and completed its Nasdaq IPO in 2025.